Multiple Myeloma — Trials

Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 814
Recruiting: 414
Ph III recruiting: 54
Growth YoY: +13.3%
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.1%
Trials / 1,000 deaths: 70.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (537)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07030517	A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma	active not recruiting	Phase 4	75	Johnson & Johnson Private LimitedINDUSTRY	1	Sep 25, 2026	clinicaltrials
NCT03829371	STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA	active not recruiting	Phase 4	450	University of Turin, ItalyOTHER	1	Dec 3, 2025